A Safety and Efficacy Study of PDFE-2304 Topical Solution for the Treatment of Androgenic Alopecia.

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 14, 2025

Primary Completion Date

August 14, 2025

Study Completion Date

September 17, 2025

Conditions

Alopecia, AndrogeneticBaldnessAndrogenetic Alopecia (AGA)

Interventions

DRUG

Minoxidil 5% Topical Solution

Approximately one mL dose applied onto a pre-specified scalp area twice daily for 16 weeks.

DRUG

PDFE-2304 Topical Solution

Approximately one mL dose applied onto a pre-specified scalp area twice daily for 16 weeks.

Trial Locations (1)

Koppal Institute of Medical Sciences, Koppal

All Listed Sponsors

lead

PDFE Pharma Innovations FZCO

INDUSTRY

NCT07011485 - A Safety and Efficacy Study of PDFE-2304 Topical Solution for the Treatment of Androgenic Alopecia. | Biotech Hunter | Biotech Hunter